SEHK:6622Pharmaceuticals
Zhaoke Ophthalmology (SEHK:6622) Stock Carries A 34.7x P/S Under Heavy Losses
Traders kept Zhaoke Ophthalmology almost flat coming into the H1 2026 report, with the stock up only about 2% over the past week. The calm price action contrasts with a much more charged reality. The company is still posting heavy losses, with H1 basic earnings per share at a loss of ¥0.22 and a net loss of ¥122.6 million.
The key issue is valuation. Zhaoke Ophthalmology trades on a P/S multiple of 34.7x, compared with the Hong Kong pharmaceuticals average near 2x. This puts every line of...